End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.65 CNY | +1.56% | -4.46% | -8.10% |
25/04 | Byhealth Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
12/04 | Byhealth Co., Ltd Approves Cash Dividend for the Year 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.10% | 3.67B | D | ||
+8.20% | 7.78B | D+ | ||
+1.64% | 7.38B | C- | ||
+10.20% | 6.52B | - | ||
-14.57% | 1.17B | - | - | |
+8.34% | 934M | - | ||
-42.27% | 879M | B+ | ||
-18.90% | 836M | C+ | ||
-16.45% | 802M | C+ | ||
+0.32% | 711M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300146 Stock
- Ratings Byhealth Co., Ltd